Effect of Prednisolone Treatment on Uterine Natural Killer Cells
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03902912|
Recruitment Status : Recruiting
First Posted : April 4, 2019
Last Update Posted : July 29, 2020
|Condition or disease||Intervention/treatment||Phase|
|Recurrent Miscarriage||Drug: Prednisolone||Phase 3|
Glucocorticoids prednisolone is considered as a potential therapy in women with recurrent miscarriage. However, the evidence for treatment with prednisolone is still inconclusive and the relevant mechanism merits further investigations.
The participants will be invited to take prednisolone oral 10 mg/day and attend our outpaitent clinic to be performed endometrial biopsy.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||84 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||The participants will be invited to take prednisolone oral 10 mg/day and attend our outpaitent clinic to be performed endometrial biopsy.|
|Masking:||None (Open Label)|
|Official Title:||Effect of Prednisolone Treatment on Uterine Natural Killer Cells and Endometrial Angiogenesis in Recurrent Miscarriage Around the Time of Embryo Implantation|
|Actual Study Start Date :||July 30, 2019|
|Estimated Primary Completion Date :||April 30, 2022|
|Estimated Study Completion Date :||April 30, 2023|
prednisolone oral 10 mg/day from day one of the subsequent menstrual cycle to day LH plus 7. Women will be then given a tailing off dose of 5 mg/day for 3 days followed by 2 mg/day for 3 days and then 1 mg/day for 3 days.
prednisolone oral 10 mg/day from day one of the subsequent menstrual cycle to day LH 7 of that cycle. Then, the participants will be given a tailing off dose of 5 mg/day for 3 days followed by 2 mg/day for 3 days and then 1 mg/day for 3 days.
- the number of uNK cells [ Time Frame: at the 1 day of endometrial biopsy ]to investigate the association between uNK cells and prednisolone
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03902912
|Contact: Hiu Tan Margaret Leeemail@example.com|
|Contact: Pui Wah Jacqueline Chung, MBBSfirstname.lastname@example.org|